Inspire Medical Systems Debt to Equity Ratio 2017-2024 | INSP
Current and historical debt to equity ratio values for Inspire Medical Systems (INSP) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Inspire Medical Systems debt/equity for the three months ending September 30, 2024 was 0.00.
| Inspire Medical Systems Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.10B | $0.70B | 0.14 |
| 2024-06-30 | $0.09B | $0.64B | 0.14 |
| 2024-03-31 | $0.10B | $0.59B | 0.16 |
| 2023-12-31 | $0.10B | $0.57B | 0.18 |
| 2023-09-30 | $0.10B | $0.54B | 0.18 |
| 2023-06-30 | $0.09B | $0.53B | 0.17 |
| 2023-03-31 | $0.07B | $0.51B | 0.13 |
| 2022-12-31 | $0.07B | $0.50B | 0.14 |
| 2022-09-30 | $0.06B | $0.47B | 0.12 |
| 2022-06-30 | $0.07B | $0.23B | 0.29 |
| 2022-03-31 | $0.07B | $0.23B | 0.29 |
| 2021-12-31 | $0.07B | $0.23B | 0.29 |
| 2021-09-30 | $0.06B | $0.22B | 0.27 |
| 2021-06-30 | $0.05B | $0.22B | 0.24 |
| 2021-03-31 | $0.05B | $0.22B | 0.23 |
| 2020-12-31 | $0.05B | $0.23B | 0.22 |
| 2020-09-30 | $0.04B | $0.23B | 0.19 |
| 2020-06-30 | $0.04B | $0.23B | 0.16 |
| 2020-03-31 | $0.04B | $0.13B | 0.30 |
| 2019-12-31 | $0.04B | $0.14B | 0.30 |
| 2019-09-30 | $0.04B | $0.15B | 0.26 |
| 2019-06-30 | $0.03B | $0.15B | 0.22 |
| 2019-03-31 | $0.03B | $0.16B | 0.20 |
| 2018-12-31 | $0.04B | $0.16B | 0.22 |
| 2018-09-30 | $0.03B | $0.10B | 0.33 |
| 2018-06-30 | $0.03B | $0.10B | 0.31 |
| 2018-03-31 | $0.03B | $-0.01B | -6.64 |
| 2017-12-31 | $0.02B | $0.00B | 17.91 |
| 2017-09-30 | $0.00B | $0.00B | 0.00 |
| 2017-06-30 | $0.00B | $0.00B | 0.00 |
| 2017-03-31 | $0.00B | $0.00B | 0.00 |
| 2016-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $5.430B | $0.625B |
| Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $38.872B | 57.28 |
| Tempus AI (TEM) | United States | $10.232B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $8.842B | 224.83 |
| IRhythm Technologies (IRTC) | United States | $3.397B | 0.00 |
| Privia Health (PRVA) | United States | $2.723B | 226.90 |
| Enovis (ENOV) | United States | $2.544B | 16.95 |
| Azenta (AZTA) | United States | $2.469B | 114.98 |
| Clover Health Investments (CLOV) | United States | $2.225B | 0.00 |
| Schrodinger (SDGR) | United States | $1.886B | 0.00 |
| Omnicell (OMCL) | United States | $1.826B | 39.83 |
| 10x Genomics (TXG) | United States | $1.773B | 0.00 |
| Phreesia (PHR) | United States | $1.680B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.937B | 0.00 |
| Talkspace (TALK) | United States | $0.608B | 0.00 |
| Standard BioTools (LAB) | United States | $0.529B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.507B | 0.00 |
| TruBridge (TBRG) | United States | $0.380B | 110.57 |
| Nyxoah SA (NYXH) | Belgium | $0.369B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.334B | 0.00 |
| Pulmonx (LUNG) | United States | $0.254B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.233B | 0.00 |
| American Well (AMWL) | United States | $0.176B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.104B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.087B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.073B | 0.00 |
| CareCloud (CCLD) | United States | $0.066B | 0.00 |
| HeartBeam (BEAT) | United States | $0.065B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.045B | 0.00 |
| Outset Medical (OM) | United States | $0.043B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.037B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.022B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.016B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.016B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.005B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |